First Health Pharmaceuticals partnership in AVITHRAPID project
First Health Pharmaceuticals is proud to be part of AVITHRAPID, the European Community funded public-private consortium for preparedness against potential pandemic viruses. Viral diseases represent a major threat to global public health. AVITHRAPID aims to establish a pipeline of early stage drug candidates based on a set of small molecules whose bioactivity against various viral targets has been already shown and which can be rapidly translated into novel antiviral agents against emerging infectious diseases with pandemic potential. In addition, the consortium will conduct a Phase 2a clinical trial for a small molecule developed against Zika virus. The AVITHRAPID research consortium…
World AIDS Day 2022 – EQUALIZE – from HIV care to HIV cure
On this World AIDS Day global leaders, WHO, NGOs and citizens join forces to address the importance of tackling the HIV epidemics in order to end AIDS. After almost three years of stagnation because of Covid19, the efforts to reach the goals that have been set over the last decades to end HIV have resumed to become a priority again. This year’s campaign is called Equalize and it is focused on reducing the inequalities that many people around the world, especially key populations like the LGTBT+ community, people who use drugs and people in prison, face regarding the access to…
Newly approved oncology patent for First Health Pharma
Our new oncology patent WO2022180080 was approved and is already available in the WIPO database. The patent protects a new generation of antitumor agents with high activity, low toxicity and a favorable pharmacological profile. FHP continues its work on clinical candidates with its improved generations of patented compounds, active against important targets such as Lung Cancer, Triple Negative Breast Cancer and Liver Cancer.
Wake up and Kill HIV
Since the publication of our Reservoir Reducing results by our partners of the Erasmus Medical Center in Nature Communications last year, several new studies by our academic partners in the Netherlands and Italy confirm these results in different assays. The Nature paper discusses a 50% reduction of the inducible HIV reservoir after a five-day treatment with our DDX3 RNA helicase inhibitor in blood of people living with HIV (PLWHIV). This ex-vivo experiment was carried out without the added use of a latency reversing agent (LRA) making it the first ever published result of HIV reservoir reduction through “shock and kill”…
In memory of Mickey Huibregtsen
It is with great sadness that we have to communicate the death of our dear friend and co-founder of First Health Pharmaceuticals, F. Wouter (Mickey) Huibregtsen. Mickey had a long and successful business career as managing director of McKinsey & Company in Amsterdam but his many contributions to society were his major driving force in life. Mickey was head of the Dutch Olympic Committee and founder of several charities and NGO’s. The annual Huibregtsen award for scientific excellence in the Netherlands was named after him. Mickey was also a co-founder and chairman of the First Health United Foundation and the…